PLYMOUTH TWP. — Delphinus Medical Technologies Inc., developers of a novel ultrasound technology for detecting breast tumors, is moving this week to a new, larger headquarters in Novi, according to a press release from the company.
The release said the new headquarters is nearly triple the size of its prior location, allowing Delphinus to expand its staff, dedicate more space to research and development, and prepare for commercialization of SoftVue, a breast ultrasound system that allows physicians to image the entire breast for diagnostic imaging purposes.
The expansion is the latest in a recent series of achievements for the company. In December 2015, on the heels of an unprecedented Series C venture round of $40 million, Delphinus added two new senior-level advisors to its board of directors, as well as a new vice president of quality and regulatory affairs.
“Our new corporate headquarters in Novi reinforces Delphinus’ commitment to transforming early detection of breast cancer and expands our presence in the Michigan community,” Delphinus president and CEO Mark J. Forchette said. “Our growth from 7,500 to 21,000 square feet is a significant expansion that will allow us to increase our lab space, double our headcount and significantly advance our R&D capability. This new facility will provide a fantastic environment for our team as we concentrate on our one and only focus: transforming early detection of breast cancer with our breakthrough SoftVue imaging technology.”
One of the additions to the new facility will be a dedicated demonstration room that will allow the company to showcase SoftVue and image review to site visitors.
As an ultrasound technology, SoftVue offers the potential to not only assist physicians in finding more cancers, but also to reduce the false positive rates that have troubled other breast imaging techniques.
SoftVue’s design incorporates a circular ultrasound transducer featuring proprietary TriAD (triple acoustic detection) technology that is unique to medical imaging. This multi-dimensional advancement presents cross-sectional ultrasound slices through the entire volume of breast tissue, capturing not only reflected echoes in a 360-degree array, but also signals passing through the breast, depicting tissue characterization.
The patented technology is a whole breast ultrasound imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan.
Delphinus was founded as a spinout of the Karmanos Cancer Institute in Detroit and is capitalized through principal investments by Arboretum Ventures and North Coast Technology Investors of Ann Arbor; Beringea of Farmington Hills; Venture Investors of Madison, Wis.; Hopen Life Science Ventures of Grand Rapids; and Waycross Ventures of Menlo Park, Calif.
For more information, visit www.delphinusmt.com.